Dana–Farber Cancer Institute

Research facility

Boston, United States (USA)

Publications in cooperation with FAU scientists

Go to first page Go to previous page 1 of 2 Go to next page Go to last page
Mayer, I.A., Prat, A., Egle, D., Blau, S., Alejandro Perez Fidalgo, J., Gnant, M.,... Arteaga, C.L. (2019). A phase II randomized study of neoadjuvant letrozole plus alpelisib for hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer (NeO-ORB). Clinical Cancer Research, 25(10), 2975-2987. https://dx.doi.org/10.1158/1078-0432.CCR-18-3160
Denkert, C., Budczies, J., Regan, M.M., Loibl, S., Dell’Orto, P., von Minckwitz, G.,... Viale, G. (2019). Clinical and analytical validation of Ki-67 in 9069 patients from IBCSG VIII + IX, BIG1-98 and GeparTrio trial: systematic modulation of interobserver variance in a comprehensive in silico ring trial. Breast Cancer Research and Treatment. https://dx.doi.org/10.1007/s10549-018-05112-9
Buckley, M.A., Woods, N.T., Tyrer, J.P., Mendoza-Fandino, G., Lawrenson, K., Hazelett, D.J.,... Freedman, M.L. (2019). Functional Analysis and Fine Mapping of the 9p22.2 Ovarian Cancer Susceptibility Locus. Cancer Research, 79(3). https://dx.doi.org/10.1158/0008-5472.CAN-17-3864
Yao, J., Garg, A., Chen, D., Capdevila, J., Engstrom, P., Pommier, R.,... Kulke, M.H. (2019). Genomic profiling of NETs: a comprehensive analysis of the RADIANT trials. Endocrine-Related Cancer, 26(4), 391-403. https://dx.doi.org/10.1530/ERC-18-0332
Capdevila, J., Bodei, L., Davies, P., Gorbounova, V., Jensen, R.T., Knigge, U.P.,... Wiedenmann, B. (2019). Unmet medical needs in metastatic lung and digestive neuroendocrine neoplasms. Neuroendocrinology, 108(1), 18-25. https://dx.doi.org/10.1159/000493319
Hoersch, D., Kulke, M.H., Caplin, M.E., Anthony, L.B., Bergsland, E., Oberg, K.,... Pavel, M.E. (2018). Efficacy and Safety of Telotristat Ethyl in Patients With Carcinoid Syndrome Inadequately Controlled by Somatostatin Analogs: Analysis of the Completed TELESTAR Extension Period. (pp. 341-342).
Lapuerta, P., Kulke, M.H., Pavel, M.E., Biran, T., Fleming, R., Zacks, J.S.,... Warner, R.R.P. (2018). Integrated Safety Analysis of Telotristat Ethyl in Patients With Carcinoid Heart Disease. (pp. 345-345).
Fazio, N., Carnaghi, C., Buzzoni, R., Valle, J., Valle, J., Herbst, F.,... Yao, J.C. (2018). Relationship between Metabolic Toxicity and Efficacy of Everolimus in Patients with Neuroendocrine Tumors (NETs): A Pooled Analysis from the Randomized, Phase 3 RADIANT-3 and RADIANT-4 Trials. (pp. 211-211).
Chan, D.L., Yao, J.C., Carnaghi, C., Buzzoni, R., Herbst, F., Herbst, F.,... Singh, S. (2018). Systemic Markers of Inflammation in Neuroendocrine Tumors (NETs) and Outcomes with Everolimus: A Pooled Analysis from the Randomized, Phase 3 RADIANT-3 and RADIANT-4 Trials. (pp. 151-151).
Pavel, M.E., Gross, D.J., Benavent, M., Perros, P., Srirajaskanthan, R., Warner, R.R.P.,... Garcia-Carbonero, R. (2018). Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial. Endocrine-Related Cancer, 25(3), 309-322. https://dx.doi.org/10.1530/ERC-17-0455
Pavel, M., Benavent, M., Perros, P., Srirajaskanthan, R., Warner, R.R.P., Kulke, M.H.,... Gross, D.J. (2018). Telotristat Ethyl in Carcinoid Syndrome: Safety and Efficacy Results of an Open-Label Extension of the TELECAST Phase 3 Clinical Trial. (pp. 350-350).
Fritchie, K., Jensch, K., Moskalev, E., Caron, A., Jenkins, S., Link, M.,... Giannini, C. (2018). The impact of histopathology and NAB2-STAT6 fusion subtype in classification and grading of meningeal solitary fibrous tumor/hemangiopericytoma. Acta Neuropathologica. https://dx.doi.org/10.1007/s00401-018-1952-6
Dillon, J., Dillon, J., Kulke, M., Warner, R., Bergsland, E., Welin, S.,... Pavel, M.E. (2018). Time to Sustained Improvement in Bowel Movement Frequency with Telotristat Ethyl: Analyses of Two Phase 3 Studies in Carcinoid Syndrome. (pp. 224-224).
Dillon, J.S., Kulke, M.H., Pavel, M.E., Horsch, D., Anthony, L.B., Warner, R.R.P.,... Lapuerta, P. (2018). Time to Sustained Improvement in Bowel Movement Frequency With Telotristat Ethyl: Analysis of the Phase 3 TELESTAR Study. (pp. 337-338).
Weickert, M.O., Kaltsas, G., Hoersch, D., Lapuerta, P., Pavel, M.E., Valle, J.W.,... Kulke, M.H. (2018). Weight Change Associated With Telotristat Ethyl in the Treatment of Carcinoid Syndrome. (pp. 357-358).
Haycock, P.C., Burgess, S., Nounu, A., Zheng, J., Okoli, G.N., Bowden, J.,... Smith, G.D. (2017). Association Between Telomere Length and Risk of Cancer and Non-Neoplastic Diseases: A Mendelian Randomization Study. JAMA Oncology, 3(5), 636-651. https://dx.doi.org/10.1001/jamaoncol.2016.5945
Kar, S.P., Adler, E., Tyrer, J., Hazelett, D., Anton-Culver, H., Bandera, E.V.,... Lawrenson, K. (2017). Enrichment of putative PAX8 target genes at serous epithelial ovarian cancer susceptibility loci. British Journal of Cancer, 116(4), 524-535. https://dx.doi.org/10.1038/bjc.2016.426
Pavel, M.E., Gable, J., Kulke, M.H., Bergsland, E., Anthony, L.B., Caplin, M.E.,... Hudgens, S. (2017). Evaluation of meaningful change in bowel move frequency for patients with carcinoid syndrome. (pp. 238-238).
Pavel, M.E., Singh, S., Strosberg, J.R., Bubuteishvili-Pacaud, L., Degtyarev, E., Neary, M.P.,... Yao, J.C. (2017). Health-related quality of life for everolimus versus placebo in patients with advanced, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (RADIANT-4): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology, 18(10), 1411-1422. https://dx.doi.org/10.1016/S1470-2045(17)30471-0
Bongaarts, A., Giannikou, K., Reinten, R.J., Anink, J.J., Mills, J.D., Jansen, F.E.,... Aronica, E. (2017). Subependymal giant cell astrocytomas in Tuberous Sclerosis Complex have consistent TSC1/TSC2 biallelic inactivation, and no BRAF mutations. Oncotarget, 8(56), 95516-95529. https://dx.doi.org/10.18632/oncotarget.20764

Last updated on 2016-15-08 at 13:52